Literature DB >> 8625541

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins.

R Y Dodd1.   

Abstract

Although intravenous immune globulin (IVIG) preparations may be derived from tens of thousands of donations, the residual risk of viral contamination of recovered plasma appears remarkably low, at least for human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Consequently, most pools are unlikely to contain these viruses although the situation is not as well understood for US-derived source plasma. In addition, routine preparation methods are likely to eliminate infectivity from the relatively fragile HIV. Current plasma screening measures are generally designed to maintain reasonable titres of anti-HBs in pools, perhaps contributing to the absence of HBV infection. The situation with respect to hepatitis C virus (HCV) is not well understood and it appears that sensitive screening for anti-HCV may have had an impact on the safety of at least one IVIG preparation. The implementation of effective viral inactivation procedures is expected to eliminate any further risk of HCV infection from IVIG preparations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625541

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  3 in total

Review 1.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

2.  Risk factors for hepatitis C virus infection among patients receiving health care in a Department of Veterans Affairs hospital.

Authors:  Girish Mishra; C Sninsky; Robert Roswell; S Fitzwilliam; Kenneth C Hyams
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

3.  Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study.

Authors:  Reem Elajez; Asmaa Ezzeldin; Hossamaldein Gaber
Journal:  Ther Adv Drug Saf       Date:  2019-10-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.